‘Link’ between AstraZeneca vaccine and blood clots, EMA official says

European Medicines Agency continues to recommend people get vaccinated, saying benefits outweigh any risks

Tom Batchelor
Tuesday 06 April 2021 18:45
Comments
Should you worry about the AstraZeneca vaccine?
Leer en Español

A senior official at the European Medicines Agency (EMA) has said he believes there is a link between the AstraZeneca vaccine and extremely rare cases of blood clots reported in people who recently had the jab.

In an interview with Italy’s Il Messaggero newspaper, Marco Cavaleri, head of vaccines strategy at the EMA, said it was “clear there is a link with the vaccine” but there was still uncertainty about what exactly was causing such a reaction.

Mr Cavaleri said that among younger vaccinated people there was a higher than expected number of cases of cerebral thrombosis – blood clotting in the brain – compared with the general population.

A spokesperson for the EMA told The Independent the Pharmacovigilance Risk Assessment Committee (PRAC), which is reviewing the data, had “not yet reached a conclusion and the review is currently ongoing”, with an announcement expected on Wednesday or Thursday.

Europe’s regulator insisted as recently as last week that the “causal link with the vaccine is not proven” and continues to recommend people take the opportunity to get vaccinated when it is offered.

Read more:

“EMA is of the view that the benefits of the AstraZeneca vaccine in preventing Covid-19, with its associated risk of hospitalisation and death, outweigh the risks of side effects,” the agency said in a statement released on 31 March.

Some countries have paused or restricted use of the vaccine to certain groups, including Germany, France and Canada.

The World Health Organisation has said the benefits outweigh the risks while AstraZeneca said in March its vaccine was 76 per cent effective in preventing symptomatic infections in a US trial, and that studies did not indicate higher risks of clotting.

Mr Cavaleri said the EMA’s evaluation of the AstraZeneca vaccine was “far from over” and that it was for individual countries to establish specific guidelines around which age groups were given which vaccines.

But he added: “In my opinion we can now say it, it is clear there is a link with the vaccine. What causes this reaction, however, we still do not know.

“These platelet-deficient cerebral thromboses appear to be the main event to investigate. In the next few hours we will say that the connection exists, but we still have to understand how this happens.”

Asked if the risk-benefit ratio was still in favour of the vaccine, he replied “yes”, but said the effects on different age groups needed to be examined “in more detail”.

He said: “Very meticulous work will be needed to understand if the risk-benefit ratio is in favour of the vaccine for all ages.”

Coronavirus-related deaths worldwide passed the 3 million mark on Tuesday, according to an assessment by the Reuters news agency.

Several European countries are experiencing a third wave of the virus, increasing the pressure on their already faltering vaccine programmes to scale up the rollout.

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Please enter a valid email
Please enter a valid email
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Please enter your first name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
Please enter your last name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
You must be over 18 years old to register
You must be over 18 years old to register
Opt-out-policy
You can opt-out at any time by signing in to your account to manage your preferences. Each email has a link to unsubscribe.

By clicking ‘Create my account’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Join our new commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in